Workpackage 7

Workpackage 7

Dose escalation by boosting radiation with the primary tumour based on a pre-treatment FDG-PET scan

 

Partners NKI (Amsterdam) and MAASTRO (Maastricht) will be collaborating in the phase II clinical trial in lung cancer patients in which PET imaging will be applied to identify areas of the tumour which show high uptake of FDG (showing resistance to treatment).  These areas of the tumour can then receive a higher radiation dose while sensitive areas (and normal tissue) can be spared. The dose to the normal tissues will however remain the same as in current standard practice, thus allowing no increase of side effects.

 

 

 

\